If a patient with NSCLC was started on a treatment regimen based on PD‐L1 expression and an actionable mutation was later identified, two‐thirds of respondents would change treatment to corresponding targeted therapy, while one‐third would either not change treatment or would change only if initial treatment was intolerable or led to progression. Here, CD274 is linked to non-small cell lung carcinoma.